JP5592890B2 - ピロロトリアジンキナーゼ阻害剤 - Google Patents

ピロロトリアジンキナーゼ阻害剤 Download PDF

Info

Publication number
JP5592890B2
JP5592890B2 JP2011531165A JP2011531165A JP5592890B2 JP 5592890 B2 JP5592890 B2 JP 5592890B2 JP 2011531165 A JP2011531165 A JP 2011531165A JP 2011531165 A JP2011531165 A JP 2011531165A JP 5592890 B2 JP5592890 B2 JP 5592890B2
Authority
JP
Japan
Prior art keywords
substituted
methyl
pyrazol
piperazinyl
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011531165A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012505234A5 (enExample
JP2012505234A (ja
Inventor
アショク・ブイ・プランデア
デイビッド・ビー・フレンネソン
ムソニ・ジー・カマウ
ラルグディ・エス・ハリクリシュナン
マーク・ジー・ソールニアー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2012505234A publication Critical patent/JP2012505234A/ja
Publication of JP2012505234A5 publication Critical patent/JP2012505234A5/ja
Application granted granted Critical
Publication of JP5592890B2 publication Critical patent/JP5592890B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2011531165A 2008-10-08 2009-10-08 ピロロトリアジンキナーゼ阻害剤 Expired - Fee Related JP5592890B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10362008P 2008-10-08 2008-10-08
US61/103,620 2008-10-08
PCT/US2009/059945 WO2010042684A1 (en) 2008-10-08 2009-10-08 Pyrrolotriazine kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2012505234A JP2012505234A (ja) 2012-03-01
JP2012505234A5 JP2012505234A5 (enExample) 2012-11-08
JP5592890B2 true JP5592890B2 (ja) 2014-09-17

Family

ID=41664941

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011531165A Expired - Fee Related JP5592890B2 (ja) 2008-10-08 2009-10-08 ピロロトリアジンキナーゼ阻害剤

Country Status (5)

Country Link
US (1) US8445676B2 (enExample)
EP (1) EP2344504B1 (enExample)
JP (1) JP5592890B2 (enExample)
CN (1) CN102245610B (enExample)
WO (1) WO2010042684A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2262806A1 (en) * 2008-03-06 2010-12-22 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CN102675323B (zh) * 2012-06-01 2014-04-09 南京药石药物研发有限公司 吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
CN104016983B (zh) * 2013-10-08 2018-11-02 上海创诺制药有限公司 吡咯并三嗪类衍生物及其制法和用途
WO2015051500A1 (zh) * 2013-10-08 2015-04-16 上海创诺制药有限公司 吡咯并三嗪类衍生物及其制法和用途
WO2015090496A1 (en) * 2013-12-17 2015-06-25 Merck Patent Gmbh N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase
CN104974163B (zh) * 2014-04-14 2017-11-07 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
US10550125B2 (en) * 2015-10-20 2020-02-04 Bristol-Myers Squibb Company Prodrugs of imidazotriazine compounds as CK2 inhibitors
HUE054912T2 (hu) * 2016-07-14 2021-10-28 Lilly Co Eli Pirazolil-amino-benzimidazol-származékok mint JAK inhibitorok
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
ES3035284T3 (en) 2020-07-02 2025-09-01 Incyte Corp Tricyclic urea compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
EP4298099A1 (en) 2021-02-25 2024-01-03 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
JP2025509672A (ja) 2022-03-17 2025-04-11 インサイト・コーポレイション Ｊａｋ２ ｖ６１７ｆ阻害剤としての三環式尿素化合物
CA3246424A1 (en) 2022-04-08 2023-10-12 Shy Therapeutics, Llc Compounds interacting with proteins of the RAS superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2373990C (en) * 1999-05-21 2007-05-08 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
CN1771234A (zh) * 2003-02-05 2006-05-10 布里斯托尔-迈尔斯斯奎布公司 吡咯并三嗪激酶抑制剂的制备方法
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
CN1993130B (zh) * 2004-06-28 2010-06-23 布里斯托尔-迈尔斯斯奎布公司 用于制备稠合杂环激酶抑制剂的方法和中间体
WO2006044687A2 (en) * 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
US7442700B2 (en) * 2005-07-01 2008-10-28 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7514435B2 (en) * 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
MX2008007103A (es) * 2005-12-02 2008-09-12 Bayer Healthcare Llc Derivados 4-amino-pirrolotriazina sustituidos, útiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis.
EP2041138B1 (en) * 2006-07-07 2014-06-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7531539B2 (en) * 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2008057994A2 (en) * 2006-11-03 2008-05-15 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
EP2134716A1 (en) * 2007-04-18 2009-12-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP5678661B2 (ja) * 2007-09-25 2015-03-04 バイエル ヘルスケア エルエルシー オーロラキナーゼの阻害による癌の治療に有用なピロロトリアジン誘導体
EP2262806A1 (en) 2008-03-06 2010-12-22 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors

Also Published As

Publication number Publication date
WO2010042684A4 (en) 2010-07-08
US8445676B2 (en) 2013-05-21
EP2344504A1 (en) 2011-07-20
CN102245610A (zh) 2011-11-16
WO2010042684A1 (en) 2010-04-15
CN102245610B (zh) 2014-04-30
JP2012505234A (ja) 2012-03-01
EP2344504B1 (en) 2014-06-04
US20110294816A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
JP5592890B2 (ja) ピロロトリアジンキナーゼ阻害剤
KR101392678B1 (ko) 피롤로트리아진 키나제 억제제
KR101828187B1 (ko) 신규 축합 피리미딘 화합물 또는 그 염
JP6267231B2 (ja) カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール
US9956220B2 (en) Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors
JP5180967B2 (ja) ピロロトリアジンキナーゼ阻害剤
CN104837844B (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
EP2049542A1 (en) Pyrrolotriazine kinase inhibitors
EP3071571A1 (en) Pyrrolopyrrolone derivatives and their use as bet inhibitors
TWI797711B (zh) 一種fgfr及其突變抑制劑，其製備方法和應用
TW202128646A (zh) 氰基取代吡啶及氰基取代嘧啶類化合物、製備方法及其應用
CN108484606B (zh) 一种嘧啶并[4,5-f]喹唑啉类化合物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140605

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140801

R150 Certificate of patent or registration of utility model

Ref document number: 5592890

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees